Bayer Sold Fake Fertility Promises to Desperate Fathers

The Non-Financial Ledger

Trying to have a child is one of the most emotionally raw experiences a person goes through. For men navigating infertility, that rawness carries a particular kind of silence. Over the past fifty years, sperm counts worldwide appear to have fallen by more than fifty percent. Fertility rates in the United States have been declining since 2007. These are not abstract statistics. They are the backdrop against which men stand in pharmacies and online storefronts, searching for something they can actually do.

Bayer saw that search and put a product on the shelf that answered it. The front of the bottle said “supports healthy sperm.” The website told men to take it for at least three months before trying to conceive. The FAQs described it as “specially formulated with key levels of powerful antioxidants” for that specific purpose. Every message in that ecosystem said: this pill is for you, and it will help.

Men bought it. Jie Chen, a resident of Queens, bought it in June 2024 for $15. He used a gift card, which is not a detail that matters legally but matters humanly. He was doing what you do when you want to be responsible. He read the label. He believed what a global pharmaceutical company printed on the front of a bottle. He paid more than five times the per-pill price of Bayer’s standard men’s vitamin because the premium version promised something the regular one did not.

The National Advertising Division found that the ingredients in the product did not support those promises. There was no substantiated science behind the claim. The fertility support framing, the “powerful antioxidants,” the instruction to start three months before conception: none of it held up when an independent review body looked at the actual evidence.

What men like Jie Chen lost was not just money. They lost months of believing they were doing something useful during one of the most stressful and hopeful periods of their lives. They were sold agency that was not real. That is the cost that does not appear in a settlement figure.

Legal Receipts

The following are direct quotes from the court filing and the NAD ruling it cites. These are on the record.

“The NAD found that certain claims, including that men should take the product for at least three months before conception and that the product is specially designed to provide nutritional support while trying to conceive, reasonably convey the message that the product improves men’s chances of conception.”

• This establishes that the NAD did not find the “supports healthy sperm” claim ambiguous. The industry’s own self-regulatory body concluded the messaging made a specific, concrete promise: that this product improves men’s chances of getting someone pregnant.
• The three-month instruction is notable. It frames the product as a clinical protocol, not just a supplement. That framing deepens consumer reliance and increases the number of bottles purchased before a buyer would ever question whether it worked.

“The NAD also found that, in the fertility-focused context, certain claims that the product supports healthy sperm reasonably convey the message that the product improves sperm health and viability.”

• The phrase “in the fertility-focused context” is critical. The NAD is saying the claim does not exist in isolation. Bayer built an entire marketing ecosystem around conception. The bottle claim, the FAQs, the website copy, and the three-month protocol all work together to create a message that is more specific and more misleading than any single phrase taken alone.

“The NAD found that the ingredient testing in the record did not support the challenged claims and recommended that Bayer discontinue or modify these claims to avoid conveying the unsupported message that the Men’s Pre-Conception Health Complete Multivitamin will improve chances of conception or that it improves sperm health and viability.”

• This is the core finding: the science does not hold up. The NAD reviewed the ingredient testing Bayer had available and concluded it was not sufficient to support what the company was telling consumers.
• The recommendation to “discontinue or modify” is the NAD’s version of a forced retraction. Bayer was not told to add a footnote. It was told the claims need to go away or be fundamentally changed.

“Had Mr. Chen known this claim was not true, he would not have purchased the OAD Product, or he would have paid less for it than he did but for Defendants’ false and misleading representations.”

• This is the standard for harm in consumer protection law: the false claim changed the buyer’s behavior. Chen paid more because he believed something that was not true. The complaint argues the same logic applies to every New Yorker who bought the product during the relevant period.
• The plaintiff also notes that he used a gift card, meaning the premium price consumed a real financial resource even if it was not cash out of pocket at that moment. The complaint specifically preserves this as a documented form of economic injury.

Public Deception

Bayer built a multi-channel messaging architecture designed to make the pre-conception multivitamin feel like a clinically grounded fertility intervention. What the NAD found when it examined the evidence tells a different story.

• What Bayer claimed: The product “supports healthy sperm,” printed on the front label of every bottle and packaging unit sold. What the NAD found: The ingredient testing in the record did not support this claim.
• What Bayer claimed: Men should take the product “for at least three months before conceiving and while trying to conceive,” framing it as a fertility preparation protocol. What the NAD found: This instruction reasonably conveyed that the product improves men’s chances of conception, a message the NAD said was not substantiated by the evidence.
• What Bayer claimed: The product is “specially formulated with key levels of powerful antioxidants … to support healthy sperm.” What the NAD found: The claims around “powerful” antioxidants, specifically lycopene, were among the challenged claims the NAD evaluated and found unsupported.
• What Bayer claimed about its research process: An “experienced team of researchers, scientists and brand enthusiasts” develops formulas based on research into “important dietary nutrients,” and products go through “over 100 rigorous quality checks.” The documented reality: Despite this stated research infrastructure, the NAD found the ingredient evidence submitted did not support the core conception and sperm health claims the product was built around.

Profit-Maximization at All Costs

The pricing structure of the One A Day Pre-Conception product makes the financial logic of this strategy visible without any inference required.

• Bayer’s standard One A Day Men’s Multivitamin retails on Amazon at $17.47 for 200 pills, or $0.09 per pill. The Pre-Conception product retails at $14.99 for 30 pills, or $0.50 per pill. The only documented difference is the fertility-focused marketing claims the NAD found to be unsubstantiated.
• The per-pill markup is more than five and a half times the price of the standard product. That price differential was charged to men who were specifically in a vulnerable, hope-driven purchasing state, trying to conceive a child.
• Bayer operates in a fertility supplement market that generated $1.754 billion in 2020 and is projected to reach $3.652 billion by 2030. The complaint establishes Bayer as a deliberate participant in this market, positioning the OAD Product to extract premium revenue from rising male infertility anxiety.
• The complaint describes the fertility context explicitly: with sperm counts down more than fifty percent globally over fifty years, and U.S. fertility rates declining since 2007, there is a documented, anxious market for products that claim to help. Bayer priced the product to match the emotional weight of that anxiety, with no substantiated science to back the premium.

Regulatory Gray Zones

Dietary supplements in the United States operate under a regulatory framework that places the burden of substantiation on the manufacturer, but does not require pre-market approval from the FDA for structure-function claims before products reach store shelves.

• The claim “supports healthy sperm” is a structure-function claim. Under current federal rules, Bayer could print this on the label without first proving it to a government agency. The FDA does not review or approve supplement claims before sale; it acts after the fact if challenged. This gap allowed Bayer to market an unsubstantiated conception benefit for years before any external review caught it.
• The NAD challenge came from a competitor, not from a regulator. The Better Business Bureau’s self-regulatory advertising division is a voluntary industry body. It can recommend changes, but it cannot force a recall, assess a fine, or mandate refunds to consumers who were misled before the ruling.
• The complaint was filed under New York General Business Law §§ 349 and 350, state consumer protection statutes, rather than federal law. This reflects the absence of a federal mechanism that would have given the same consumers direct redress for this specific type of misleading supplement claim.

How Capitalism Exploits Delay: Time as a Corporate Weapon

The timeline of this case demonstrates how a product can be sold with unsubstantiated health claims for an extended period before any accountability mechanism produces a remedy for consumers who already paid.

• The plaintiff purchased the product in June 2024. The NAD ruling recommending Bayer discontinue or modify the claims was issued March 31, 2026, nearly two years later. During that window, and for however long before Chen’s purchase the product was on the market, consumers paid the premium price for claims that did not hold up.
• The class action complaint was filed on May 6, 2026, five weeks after the NAD ruling. The lawsuit process itself may take years. Any consumer who bought the product before the applicable statute of limitations cutoff and does not participate in the class will receive nothing.
• The three-month consumption protocol Bayer advertised is its own delay mechanism in practice: buyers are instructed to commit to multiple bottle purchases before evaluating whether the product is working. A buyer following that instruction would have spent at minimum $45 on three bottles before they would even have a data point on efficacy.

Societal Impact Mapping

Public Health

The harm here is concentrated at the intersection of fertility anxiety and unregulated supplement marketing.

• Men who used this product as a fertility intervention during a period of active conception attempts may have delayed seeking actual medical evaluation, believing a supplement was handling the problem. The complaint does not document specific health outcomes, but the three-month consumption protocol Bayer prescribed is long enough to constitute a meaningful delay in a fertility timeline.
• Global sperm counts have declined by more than fifty percent over the past fifty years, and U.S. fertility rates have been falling since 2007. This is a genuine public health context. Products that falsely claim to address that trend without substantiated science consume the trust and resources of people who genuinely need effective interventions.
• The fertility supplement market is projected to reach $3.652 billion by 2030. Bayer’s unsubstantiated claims contribute to a broader market norm where sellers profit from fertility anxiety without being required to prove their products work before reaching consumers.

Economic Inequality

The financial harm from this product fell disproportionately on buyers who could least afford a premium that delivered nothing beyond standard vitamin content.

• The OAD Pre-Conception product cost $0.50 per pill versus $0.09 per pill for a standard men’s multivitamin. For a buyer following Bayer’s own three-month protocol, that difference amounts to spending approximately $45 on pre-conception-branded pills versus approximately $8.10 on the standard variant, a difference of roughly $37 for ingredients the NAD found were not substantiated to do anything additional.
• The plaintiff, Jie Chen, purchased the product on Amazon using a gift card. The complaint preserves the gift card expenditure as a documented economic injury, which speaks to the reality that consumers at various income levels make these purchases. A $15 bottle representing a meaningful financial decision for one consumer and a rounding error for another does not change that both paid a false premium.
• Class actions are the primary mechanism available to consumers harmed by low-dollar, high-volume deception. The complaint notes that individual damages are “relatively small compared to the burden and expense entailed by individual litigation.” Without the class mechanism, Bayer would face no practical accountability from any individual buyer.

The “Cost of a Life” Metric

This Is the System Working as Intended

Every mechanism that allowed this to happen was functioning exactly as designed. Nothing broke down. Nothing failed. The outcome was predictable from the structure.

• The FDA does not review dietary supplement structure-function claims before products go on sale. Bayer was not required to prove the “supports healthy sperm” claim to any government body before printing it on millions of bottles. The regulatory gap is not an accident; it is the result of lobbying and legislative choices that have defined supplement regulation for decades.
• The entity that caught the false claim was a competitor, not a regulator. Industry self-regulation through the NAD exists precisely because it is less disruptive to corporations than government enforcement. The NAD can recommend; it cannot fine, recall, or compel restitution to consumers already harmed.
• The class action mechanism, which is the only practical legal tool available to the thousands of consumers who paid the false premium, will take years to resolve and may end in a settlement that returns cents on the dollar to individual buyers while attorneys collect fees. This is the intended channeling of consumer grievance into a process that minimizes the cost to the corporation while providing the appearance of accountability.
• Bayer is described in the complaint as “a life science company and a global leader in healthcare and nutrition.” That brand authority is itself a product of the system. Consumers bought this supplement partly because Bayer’s name carries weight. The company monetized trust it built in legitimate pharmaceutical markets and applied it to a health claim that did not hold up to scrutiny.

What a Legitimate Fix Looks Like

The core structural failure this case exposes: manufacturers of dietary supplements can market products with specific, clinical-sounding health claims targeting vulnerable consumers without proving those claims to any regulatory body before the products reach store shelves.